What is Leerink Partnrs’ Estimate for ALDX FY2028 Earnings?

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) – Research analysts at Leerink Partnrs reduced their FY2028 earnings per share (EPS) estimates for shares of Aldeyra Therapeutics in a report released on Wednesday, November 13th. Leerink Partnrs analyst M. Goodman now expects that the biotechnology company will post earnings of $2.50 per share for the year, down from their previous estimate of $2.55. The consensus estimate for Aldeyra Therapeutics’ current full-year earnings is ($0.48) per share.

Separately, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Aldeyra Therapeutics in a research note on Friday, August 9th.

Aldeyra Therapeutics Stock Performance

Shares of ALDX stock opened at $4.27 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.80 and a current ratio of 6.80. The business has a fifty day simple moving average of $5.53 and a 200-day simple moving average of $4.60. Aldeyra Therapeutics has a fifty-two week low of $2.43 and a fifty-two week high of $6.55.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, meeting the consensus estimate of ($0.25).

Institutional Trading of Aldeyra Therapeutics

Institutional investors have recently made changes to their positions in the stock. US Bancorp DE purchased a new position in shares of Aldeyra Therapeutics in the 3rd quarter valued at $30,000. SG Americas Securities LLC acquired a new position in shares of Aldeyra Therapeutics in the 2nd quarter worth approximately $38,000. Diversified Trust Co acquired a new stake in shares of Aldeyra Therapeutics during the second quarter worth $41,000. Laidlaw Wealth Management LLC boosted its stake in Aldeyra Therapeutics by 32.6% in the second quarter. Laidlaw Wealth Management LLC now owns 16,875 shares of the biotechnology company’s stock valued at $56,000 after acquiring an additional 4,150 shares during the period. Finally, Paloma Partners Management Co bought a new position in Aldeyra Therapeutics during the 3rd quarter worth $62,000. 59.71% of the stock is owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.